References in periodicals archive ?
The UK's National Institute for Health and Care Excellence (NICE) has delivered a positive final appraisal determination (FAD) for Merck's Erbitux (cetuximab) to treat patients with RAS wild-type metastatic colorectal cancer (mCRC), the pharma manufacturer announced on Thursday.
The results demonstrate that Erbitux (cetuximab) plus FOLFOX statistically significantly improves outcomes, including progression-free survival (PFS; primary endpoint), overall survival (OS) and best overall response rate (bORR), compared with FOLFOX alone1.
In February 2004, Eli Lilly/BMS/Merck KGaA's Erbitux (cetuximab) became the first monoclonal antibody to be approved by the FDA for metastatic CRC.
The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.
In North America, Erbitux is marketed by Merck KGaA and Bristol-Myers, and ImClone co-promotes Erbitux in North America with Bristol-Myers.
But now I don't think there is any alternative to Erbitux and I have been turned down.
NICE boss Andrew Dillon said its advisory committee it did not feel Erbitux "works any better than existing treatments".
In January, Nice also rejected an appeal from charities over its decision to reject Erbitux for bowel cancer patients.
Charities Cancerbackup and Bowel Cancer UK appealed against a decision by the health watchdog to reject the drug Erbitux (cetuximab) for use on the NHS.
Which is why Ms Hewitt should allow wonder drug Erbitux to be prescribed on the NHS despite its pounds 11,500 cost.
The watchdog rejected Avastin (bevacizumab) and Erbitux (cetuximab) for treating advanced bowel cancer, saying the drugs were not cost-effective.